Who is affected by this change?

This affects Independence Blue Cross Gastroenterology providers on Commercial plans.

When does this change take effect?

This change is effective Nov 26, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.01.18i, Vedolizumab (Entyvio®) for Injection for Intravenous Use

Independence Blue Cross·Gastroenterology·Pharmacy

Effective date

Nov 26, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

IBX Commercial policy for Vedolizumab (Entyvio®) injections has been reissued effective November 26, 2025. This is a pharmacy policy update that may affect coverage or authorization requirements for this IV medication used primarily for inflammatory bowel diseases.

Action Required

Action needed

By November 26, 2025: Review updated IBX Commercial policy for Vedolizumab (Entyvio®) at the provided URL to identify any changes to prior authorization, coverage criteria, or billing requirements. Update billing protocols and inform providers of any new requirements for this IV medication.

Related policy hubs

Independence Blue Cross policies Gastroenterology